Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAH-p53-8 is a hydrocarbon-stapled alpha-helical peptide designed to mimic the transactivation domain of the p53 tumor suppressor protein. It functions as a dual inhibitor of the p53-MDM2 (HDM2) and p53-MDMX (HDMX) interactions. By competitively binding to the p53-binding pockets of these negative regulators, SAH-p53-8 prevents the ubiquitination and degradation of p53, thereby restoring its ability to induce cell cycle arrest and apoptosis in cancer cells harboring wild-type p53. Preclinical studies, particularly in metastatic melanoma, have shown that SAH-p53-8 can sensitize tumor cells to conventional chemotherapy and arrest tumor growth in vivo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SAH-p53-8.